Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglycosides: current role in antimicrobial therapy.

B A Cunha1

  • 1Infectious Disease Division, Winthrop-University Hospital, Mineola, NY 11501.

Pharmacotherapy
|January 1, 1988
PubMed
Summary

Aminoglycosides are crucial for treating gram-negative infections, especially in cancer patients. Amikacin shows promise as a leading aminoglycoside due to its efficacy, safety, and cost-effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Viral influenza-like illnesses: dynamic interrelationships during the 2015-2016 influenza season in hospitalized patients.

The Journal of hospital infection·2017
Same author

Editor's Mail.

Postgraduate medicine·2016
Same author

Are atypical lymphocytes present with viral influenza-like illnesses (ILIs) in hospitalized adults?

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2016
Same author

Problems+Solutions.

Postgraduate medicine·2016

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Oncology

Background:

  • Aminoglycosides are essential for treating nosocomial gram-negative bacillary infections.
  • Despite newer antibiotics, aminoglycosides maintain a key role in treating infections like gram-negative urosepsis and febrile granulocytopenic patients.
  • Their established antipseudomonal activity is critical for empiric therapy in immunocompromised patients.

Purpose of the Study:

  • To evaluate the role and efficacy of aminoglycosides in treating gram-negative infections.
  • To identify the most effective aminoglycoside based on resistance, pharmacokinetics, safety, and cost.

Main Methods:

  • Review of current literature on aminoglycoside use in nosocomial infections.
  • Analysis of resistance rates, pharmacokinetic data, safety profiles, and cost-effectiveness of different aminoglycosides.
  • Comparison of amikacin with other aminoglycosides based on these parameters.

Main Results:

  • Aminoglycosides are vital for treating gram-negative infections, particularly in febrile granulocytopenic cancer patients when combined with beta-lactams.
  • Amikacin demonstrates favorable resistance rates, pharmacokinetic properties, safety, and cost-effectiveness.
  • These factors position amikacin as a highly effective aminoglycoside option.

Conclusions:

  • Aminoglycosides remain a cornerstone in managing serious gram-negative infections.
  • Amikacin emerges as a leading choice due to its comprehensive profile of efficacy, safety, and economic considerations.
  • Continued use and evaluation of aminoglycosides, particularly amikacin, are warranted in clinical practice.

Related Experiment Videos